Liraglutide - Novo Nordisk

Drug Profile

Liraglutide - Novo Nordisk

Alternative Names: LATIN T1D; Liraglutide; NN 2211; NN 9211; NN-8022; NNC 90-1170; Saxenda; Victoza

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novo Nordisk
  • Developer Cedars-Sinai Medical Center; Hvidovre Hospital; Novo Nordisk
  • Class Antihyperglycaemics; Glucagon-like peptides; Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity; Type 2 diabetes mellitus
  • Phase II Parkinson's disease
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 21 Nov 2017 Health Canada approves liraglutide (Adjunctive treatment) to reduce the risk of cardiovascular death in patients with Type 2 diabetes and established cardiovascular disease
  • 11 Nov 2017 Updated efficacy data from the phase III LEADER trial in Type-2 diabetes mellitus presented at the 90th Annual Scientific Sessions of the American Heart Association (AHA/ASA-2017)
  • 09 Nov 2017 Novo Nordisk completes a phase III trial in Type-2 diabetes mellitus (Adjunctive treatment) in Japan (SC) (NCT02505334)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top